PostEra enters into strategic alliance with Pfizer Inc. to advance drug discovery
Tuesday, December 08, 2020
PostEra , a biotechnology company specializing in machine learning solutions for preclinical drug discovery, announced a strategic alliance with Pfizer Inc. with the goal of to accelerate the discovery of small molecule drugs by developing a platform technology based on generative chemistry.
PostEra's machine-based learning technology aims to accelerate the drug discovery process by designing novel molecular structures with optimized potency and pharmacological properties. PostEra's approaches take into account chemical synthesis as well as the design assumptions of medicinal chemists.
Through collaboration, the companies will leverage Pfizer's extensive data and expertise with PostEra technology capabilities to advance the science of generative chemistry to produce cutting-edge scalable models that could be deployed in in-house, preclinical drug discovery efforts.
PostEra will receive an initial payment and is eligible to receive additional payments as the project progresses. PostEra will also maintain proprietary rights to all algorithms developed during the collaboration.
"PostEra is delighted to be working with Pfizer to address some of the key pain points in preclinical drug discovery," said Aaron Morris , CEO of PostEra. "As a team we are proud to enter this collaboration and will take advantage of PostEra's many advancements in machine-based learning to help Pfizer accelerate progress towards new therapeutics.
"We believe that our investments in machine learning technologies could potentially help accelerate preclinical drug discovery. PostEra's technology complements this effort and we look forward to seeing the results of the collaboration," said Charlotte Allerton , Director of Medicine Design. , Pfizer.
